A phase 1 study of ABT-806 in subjects with advanced solid tumors. (Q50561813)

15 March 2018

title

A phase 1 study of ABT-806 in subjects with advanced solid tumors. (English)

1 reference

15 March 2018

Leena Gandhi

4

0 references

David A Reardon

2

object named as

David A Reardon

1 reference

15 March 2018

James M Cleary

1

1 reference

15 March 2018

Nilofer Azad

3

1 reference

15 March 2018

Geoffrey I Shapiro

5

1 reference

15 March 2018

Jorge Chaves

6

1 reference

15 March 2018

Michelle Pedersen

7

1 reference

15 March 2018

Peter Ansell

8

1 reference

15 March 2018

William Ames

9

1 reference

15 March 2018

Hao Xiong

10

1 reference

15 March 2018

Wijith Munasinghe

11

1 reference

15 March 2018

Matt Dudley

12

1 reference

15 March 2018

Edward B Reilly

13

1 reference

15 March 2018

Kyle Holen

14

1 reference

15 March 2018

Rod Humerickhouse

15

1 reference

15 March 2018

publication date

17 April 2015

1 reference

15 March 2018

Investigational New Drugs

published in

1 reference

15 March 2018

volume

33

1 reference

15 March 2018

page(s)

671-678

1 reference

15 March 2018

issue

3

1 reference

15 March 2018

https://scigraph.springernature.com/pub.10.1007/s10637-015-0234-6

exact match

0 references

cites work

EGFR antagonists in cancer treatment

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0234-6

Transgenic and knock-out mice for deciphering the roles of EGFR ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0234-6

The epidermal growth factor receptor as a target for therapy in breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0234-6

Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0234-6

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0234-6

Cetuximab for the treatment of colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0234-6

Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0234-6

Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0234-6

Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0234-6

A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0234-6

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0234-6

Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0234-6

Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0234-6

Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0234-6

Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0234-6

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0234-6

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0234-6

A case of penile squamous cell carcinoma treated with a combination of antiepidermal growth factor receptor antibody and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0234-6

Epidermal growth factor receptor-targeted therapy in squamous cell carcinoma of the penis: a report of 3 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0234-6

The epidermal growth factor receptor is frequently overexpressed in penile squamous cell carcinomas: a tissue microarray and digital image analysis study of 112 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0234-6

Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0234-6

Epidermal growth factor receptor (EGFR)-RAS signaling pathway in penile squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0234-6

Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck.

21 January 2018

1 reference

12 December 2020

Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.

1 reference

12 December 2020

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

1 reference

12 December 2020

Tyrosine kinases as targets for cancer therapy

1 reference

12 December 2020

Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors

1 reference

12 December 2020

Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.

1 reference

12 December 2020

Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments

1 reference

12 December 2020

Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results

1 reference

12 December 2020

Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.

1 reference

12 December 2020

Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers

1 reference

12 December 2020

10.1007/S10637-015-0234-6

Identifiers

DOI

1 reference

15 March 2018

PubMed ID

25895099

1 reference

15 March 2018